Member Info for milktrayman69

Yes 1 or 2 of them

Finally we get some news of an EU deal ! About time i say , if i am honest with you lot , i was expecting a bigger reaction to the market on this news, oh well! Anyway I like the fact that it is not a bigger distributor based on the shenanigans we have had in the past with them . I love the fact that that Coopers did their own due diligence to confirm FUM clinical findings in their own manner before putting ink to paper. That is now 5 commercial licensing agreements and next stop the submission to the FDA. Cannot wait for Coopers to launch this product this year hopefully for us to finally start sleeping at night !! Well done all long term holders , we seem to finally seeing some things going our way.

Its a waiting game with this one , Mr Barder has the enthusiasm of a worm at the start of a 100 m sprint! Anyway all we can do is wait and trust these guys are on it with the UK/EU deal and the submission of the FDA study. Really hoping to hear news soon on some UK/EU partnership deal that we have been so eagerly waiting .

The Italian , this could imply a more online presence potentially for licensing partners perhaps as opposed to traditional walk in to a chemist and buy of the counter, again only trying to dicpher his comments on my own opinion

just to add on the Product pipeline :

Over the next 4 years post med3000 launch some products in the pipeline:

Premature ejaculation product
Mousse format of med 3000
Med 3000 in small pouch/sachet in carry around
Product for female sexual dysfunction

Just come off webex , here are my notes to share :

• Price likely to be £5 per tube
• Product launch in the next year - next 12 months basically is what the Finance person alluded to
• Target younger audience as well due to exposure to pornography
• OTC - 73 % will likely to be new patients currently not on treatment based on research
• Build a sustainable and profitable brand through commercial agreements - focus on key performance obligations for partners baked into agreement
• Only look at commercial partners who we feel are credible
• Priority of EU/UK market - discussions going well
• FUM will control manufacture and not partners
• US - have had enquiries from potential partners but our focus is currently in the FDA approval
• Later this year looking at commercialisation
• FDA approval will de risk the project for us
• Starting formal process for securing commercial opportunities in Q4 2022 in US

FDA submission

Q3 September 2022 results of FM71
Submission of med 3000 application straight after that

Product pipeline

Looks good with various formats for the ED gel in pouches etc to carry around
Female products in pipeline

Period of exclusivity can only remain for a short period and i doubt that it will stay until FDA approval is gained. I would have thought that the buyer would stipulate the exclusivity period to ensure they have done all their due diligence before committing to a deal/agreement. so i translate this as further down the sales cycle. as it may involve an upfront payment ?

Cannot, remember, did they share results of previous trials to investors before submitting to EU for approval? Do not think they did from memory?

I would also love to hear some news on UK/EU deal or RNS before presentation , though, do companies generally announce an RNS just before an investor presentation ?

Its going to take more than just an intermittent rns here and there on new partners onboarding to move this SP as is evident today. Don't think LTH have the same level of patience as we used to , been invested and been following this for years now . We need a europe/uk deal to come in and launch of product on shelves in multiple regions to really kick this SP into touch again , i invested in the potential of this share and still believe in it , but the execution of the BOD and lack of detail and clarity has left me frustrated . As a poster said earlier , you have an Italian based firm looking to spin up activity in Korea , why not spin up activity in Europe where the barriers to entry have been tackled already with the CE cert as one example. All the above is my opinion of course !

Of course blue diamond, they won deals in MENA, Portugal etc and even launched the damn product in a European country and had positive feedback capturing 15% of the market share apparently in a short space of time for that region . The likes of reckitt and dwight and co were even on board at the time with exclusive rights. FUM must learn from the mistakes from the past as the market has a good memory . Continued communication is key for investors and we need to see something on shelves as well as a deal in Europe/UK soon otherwise the market will go limp again on FUM. The US FDA is not until Q1 2023 and of course is the biggest addressable market but the market is getting tired of this prolonged 4 play and needs to see some action now

Interestingly the commercial deals never talk about numbers though , how much the deal is worth or what the upfront payment is etc..

We will not see US FDA approval until q1 2023 , so the significant news this year will be the initial launches of the product into key regions. We have got from the RNS that the focus for FUM is the top 15 countries for ED of which UK is 6th . So interested when the UK/Europe commercial deal is likely to land?

Not convinced by the buyout opinion personally , why would they go to lengths to arrange a manufacturing and distribution agreement with a manufacturer? Anyway , we can all speculate , the news today is of course welcome and another step to global coverage . Todays share price rise reflects again the sentiment of the market , which is "great you have a deal , but when is the initial launch " , initial launch is when i see the market really being convinced by the BOD as we have been down this road before with FUM and CSD. This time though is different as we have the CE mark , however we seem to be sitting on it , Q2 is when we have been told of an initial launch ,so let us see. For those who can , it is most definitely a good time to buy or top up.

thanks herdie, useful article to share

Can anyone copy and paste article here?

Agree, incidentally, have we secured any European partner to date or more to the point a partner in the UK ?

They say the proof is in the pudding. You approach a potential partner and say "hey we have a fantastic product that will outcompete viagra and cialis in the space of erectile dysfunction, our unique selling point is the onset of an erection in less than 10 mins allowing for spontaneous and unplanned sex" . The partner says "great, have you got figures to prove the success of this commercially " . FUM " err no we have not launched it yet but we have many partners we have lined up who have shown great interest and we are focusing on our manufacturing in the likelihood we get a deal" . How would that sit with you as an interested partner?

No news is good news as they say , not sure about that on this one . For comms this company is not good , bloody hope the next RNS has meaningful information apart form the "we are working on partner deals". The current Sp accurately reflects the sentiment of shareholders who are left in the dark. 2022 according to them was the breakthrough year, well dont hold your breath. PS not a deramper but a frustrated LTH !

Really hoping 2022 is the year they finally get that $%^& out the door , based on their last RNS "Scale-up of manufacturing and production capacity to meet projected demand continues to progress well as Futura works towards an initial launch of MED3000 in certain countries in 2022."